AVPT vs PTRN

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid revenue growth (23.6% YoY) and strong gross margins (74.51%), profitability remains thin with only a 0.50% net margin and weak ROE (0.67%). Analysts recommend a 'buy' with a $19.02 target, implying 51% upside, but insider selling of $89.11M over the last six months contradicts this optimism. The stock trades at a high forward P/E of 32.18, above sector averages, while recent price performance is bearish (-31.3% over 1Y), reflecting market skepticism despite improving earnings trends.

PTRN presents a stark contrast between strong growth metrics and poor operational health, as evidenced by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 40.30% and a reasonable Forward P/E of 23.01, its net profit margins are razor-thin at 0.65%. The balance sheet is clean with very low debt (D/E 0.05) and strong liquidity (Current Ratio 2.34), but the lack of operational efficiency drags down the deterministic health scores. The stock is currently viewed as a speculative growth play with a significant gap between its current price and analyst targets.